克洛己新、复方异丙托溴铵及布地奈德混悬液三联治疗小儿毛细支气管炎的临床疗效

Clinical efficacy of triple combination therapy of cefaclor,compound ipratropium bromide and budesonide suspension for bronchiolitis in children

目的探究克洛己新、复方异丙托溴铵及布地奈德混悬液三联治疗小儿毛细支气管炎的临床疗效。方法90例小儿毛细支气管炎患儿,按照随机数表法分为三联组及对照组,各45例。对照组给予复方异丙托溴铵+布地奈德混悬液治疗,三联组在对照组基础上联合克洛己新治疗。比较两组患儿临床疗效、症状消失时间以及治疗前后生化指标[超敏C反应蛋白(hs-CRP)、降钙素原(PCT)]。结果治疗2周后,三联组治疗总有效率93.33%高于对照组的77.78%,差异具有统计学意义(P<0.05)。三联组患儿咳嗽停止时间(5.46±0.87)d、憋喘消失时间(4.67±0.58)d、退烧时间(8.24±2.34)d均短于对照组的(6.63±1.65)、(5.46±1.03)、(10.31±2.15)d,差异均具有统计学意义(P<0.05)。治疗2周后,两组患儿hs-CRP、PCT较治疗前显著降低,且三联组患儿hs-CRP(2.63±0.42)mg/L、PCT(0.35±0.04)ng/ml均低于对照组的(3.76±1.14)mg/L、(0.46±0.08)ng/ml,差异均具有统计学意义(P<0.05)。结论克洛己新、复方异丙托溴铵及布地奈德混悬液三联治疗小儿毛细支气管炎效果良好,可显著改善患儿呼吸道症状,减轻机体炎症反应。

Objective To investigate the clinical efficacy of triple combination therapy of cefaclor,compound ipratropium bromide and budesonide suspension for bronchiolitis in children.Methods A total of 90 children with bronchiolitis were divided into triple groups and control group according to the random numerical table,with 45 cases in each group.The control group was treated with compound ipratropium bromide and budesonide suspension,and the triple group was treated with cefaclor on the basis of the control group.Both groups were compared in terms of clinical efficacy,symptoms disappearance time and biochemical indicators[high-sensitivity C-reactive protein(hs-CRP),procalcitonin(PCT)]before and after treatment.Results After 2 weeks of treatment,the total effective rate 93.33%of the triple group was higher than 77.78%of the control group,and the difference was statistically significant(P<0.05).The disappearance time of cough(5.46±0.87)d,disappearance time of wheezing(4.67±0.58)d,and fever reduction time(8.24±2.34)d in the triple group were shorter than(6.63±1.65),(5.46±1.03),and(10.31±2.15)d in the control group,and the difference was statistically significant(P<0.05).After 2 weeks of treatment,hs-CRP and PCT of the two groups were significantly lower than those of this group before treatment,and hs-CRP(2.63±0.42)mg/L and PCT(0.35±0.04)ng/ml of the triple group were lower than(3.76±1.14)mg/L and(0.46±0.08)ng/ml of the control group.All the differences were statistically significant(P<0.05).Conclusion Triple combination therapy of cefaclor,compound ipratropium bromide and budesonide suspension has good effect on children with bronchiolitis,and it can significantly improve the respiratory symptoms and relieve the body’s inflammatory response.